MX2023005338A - Compuestos macrociclicos sustituidos y metodos de tratamiento relacionados. - Google Patents
Compuestos macrociclicos sustituidos y metodos de tratamiento relacionados.Info
- Publication number
- MX2023005338A MX2023005338A MX2023005338A MX2023005338A MX2023005338A MX 2023005338 A MX2023005338 A MX 2023005338A MX 2023005338 A MX2023005338 A MX 2023005338A MX 2023005338 A MX2023005338 A MX 2023005338A MX 2023005338 A MX2023005338 A MX 2023005338A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- related methods
- macrocyclic compounds
- substituted macrocyclic
- substituted
- Prior art date
Links
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
- 208000001573 Cataplexy Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063128404P | 2020-12-21 | 2020-12-21 | |
| US202163190937P | 2021-05-20 | 2021-05-20 | |
| PCT/US2021/064483 WO2022140316A1 (en) | 2020-12-21 | 2021-12-21 | Substituted macrocyclic compounds and related methods of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005338A true MX2023005338A (es) | 2023-05-22 |
Family
ID=80050560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005338A MX2023005338A (es) | 2020-12-21 | 2021-12-21 | Compuestos macrociclicos sustituidos y metodos de tratamiento relacionados. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12006330B2 (enExample) |
| EP (1) | EP4263555A1 (enExample) |
| JP (1) | JP2024501641A (enExample) |
| KR (1) | KR20230127254A (enExample) |
| CN (1) | CN116615427B (enExample) |
| AU (1) | AU2021409403A1 (enExample) |
| CA (1) | CA3172841A1 (enExample) |
| IL (1) | IL303848A (enExample) |
| MX (1) | MX2023005338A (enExample) |
| WO (1) | WO2022140316A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260083444A (ko) | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| EP4247801A4 (en) * | 2020-11-23 | 2024-10-30 | Merck Sharp & Dohme LLC | 3-AMINO PYRROLIDINE AND MACROCYCLIC PIPERIDINE OREXIN RECEPTOR AGONISTS |
| US12006330B2 (en) * | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| WO2022207935A1 (en) | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
| WO2022232025A1 (en) * | 2021-04-26 | 2022-11-03 | Alkermes, Inc. | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity |
| JP7833486B2 (ja) * | 2021-05-26 | 2026-03-19 | アルカーメス，インコーポレイテッド | 置換されるカルバメート大環状化合物および関連のある治療方法 |
| AU2022281345A1 (en) * | 2021-05-26 | 2023-11-30 | Alkermes, Inc. | Substituted fused bicyclic macrocyclic compounds and related methods of treatment |
| CN120584118A (zh) * | 2022-11-23 | 2025-09-02 | 沃泰克斯药物股份有限公司 | 食欲素受体2的经取代的大环胺调节剂 |
| JP2026506356A (ja) * | 2023-01-31 | 2026-02-24 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 大環状オレキシン受容体アゴニスト及びその使用 |
| EP4680611A1 (en) * | 2023-03-16 | 2026-01-21 | Takeda Pharmaceutical Company Limited | Macrocyclic heterocycle compounds and use thereof |
| JP2026518313A (ja) | 2023-06-01 | 2026-06-04 | ハー・ルンドベック・アクチエゼルスカベット | スピロ大環状オレキシン２受容体アゴニスト |
| WO2025096445A1 (en) * | 2023-10-30 | 2025-05-08 | Alkermes, Inc. | Synthesis of intermediates for the preparation of macrocyclic compounds |
| CN122374291A (zh) | 2023-12-12 | 2026-07-10 | 爱杜西亚药品有限公司 | 作为食欲素受体调节剂的芳基砜及砜酮衍生物 |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
| WO2026017128A1 (zh) * | 2024-07-17 | 2026-01-22 | 江苏恩华药业股份有限公司 | 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途 |
| US20260109711A1 (en) * | 2024-09-18 | 2026-04-23 | Vertex Pharmaceuticals Incorporated | Macrocyclic sulfonamide modulators |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8258163B2 (en) | 2008-06-04 | 2012-09-04 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
| US9527807B2 (en) | 2011-04-05 | 2016-12-27 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| EP2836485B1 (en) | 2012-03-17 | 2018-01-10 | Polyphor Ag | Conformationally constrained, fully synthetic macrocyclic compounds |
| WO2014198880A1 (en) | 2013-06-14 | 2014-12-18 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
| US20160250224A1 (en) | 2013-09-24 | 2016-09-01 | The Board Of Regents Of The University Of Texas System | Orexin-control of bone formation and loss |
| WO2015073707A1 (en) | 2013-11-15 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating heart failure with agonists of hypocretin receptor 2 |
| SG11201604639YA (en) | 2013-12-12 | 2016-07-28 | Univ Tsukuba | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof |
| JP6552117B2 (ja) | 2014-03-28 | 2019-07-31 | 国立大学法人 筑波大学 | 敗血症の予防治療剤 |
| JP6715239B2 (ja) | 2014-09-11 | 2020-07-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換２−アザ二環式化合物及びオレキシン受容体調節因子としてのその使用 |
| WO2016133160A1 (ja) | 2015-02-19 | 2016-08-25 | 国立大学法人筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
| CA2989146A1 (en) | 2015-06-12 | 2016-12-15 | Board Of Regents, The University Of Texas System | Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof |
| SG11201806429PA (en) | 2016-02-04 | 2018-08-30 | Takeda Pharmaceuticals Co | Substituted piperidine compound and use thereof |
| JP7012703B2 (ja) | 2017-03-08 | 2022-02-14 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| JP6957598B2 (ja) | 2017-03-08 | 2021-11-02 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| US11319286B2 (en) | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| US10428023B2 (en) | 2017-08-03 | 2019-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| CN111132975B (zh) | 2017-09-28 | 2023-05-23 | 勃林格殷格翰国际有限公司 | N-(2,2-二氟乙基)-n-[(嘧啶基氨基)丙基]芳基甲酰胺 |
| JP7170996B2 (ja) | 2017-12-12 | 2022-11-15 | 国立大学法人 筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
| WO2019191327A1 (en) | 2018-03-27 | 2019-10-03 | Board Of Regents, The University Of Texas System | Ox2r compounds |
| EP3816154B1 (en) | 2018-06-29 | 2025-04-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| US11655241B2 (en) | 2018-06-29 | 2023-05-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| JP7379374B2 (ja) | 2018-12-12 | 2023-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
| JP7408569B2 (ja) | 2018-12-12 | 2024-01-05 | 武田薬品工業株式会社 | 複素環化合物 |
| PE20211700A1 (es) | 2019-01-31 | 2021-09-01 | Takeda Pharmaceuticals Co | Compuesto heterociclico y su uso |
| US11098029B2 (en) | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| WO2020167701A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor agonists |
| EP4010314B1 (en) | 2019-08-08 | 2024-02-28 | Merck Sharp & Dohme LLC | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| JP2022547604A (ja) | 2019-09-13 | 2022-11-14 | 武田薬品工業株式会社 | 過度の眠気の治療のためのオレキシン２受容体アゴニストの使用 |
| KR20260083444A (ko) | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| WO2021106975A1 (ja) | 2019-11-27 | 2021-06-03 | 武田薬品工業株式会社 | 複素環化合物 |
| US11352357B2 (en) | 2019-11-27 | 2022-06-07 | Sumitomo Dainippon Pharma Co., Ltd. | Cycloalkylurea derivative |
| CA3167050A1 (en) | 2020-01-10 | 2021-07-15 | Takeda Pharmaceutical Company Limited | A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450 |
| CN119235864A (zh) | 2020-07-17 | 2025-01-03 | 卫材R&D管理有限公司 | 取代的哌啶化合物及其用途 |
| US20230365533A1 (en) | 2020-08-18 | 2023-11-16 | Merck Sharp & Dohme Llc | Bicycloheptane pyrrolidine orexin receptor agonists |
| WO2022040058A1 (en) | 2020-08-18 | 2022-02-24 | Merck Sharp & Dohme Corp. | Cyclopentapyrrole orexin receptor agonists |
| CN116635393A (zh) | 2020-09-03 | 2023-08-22 | 欧瑞夏治疗有限公司 | 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途 |
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| JP2022064180A (ja) | 2020-10-13 | 2022-04-25 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2022094012A1 (en) | 2020-11-02 | 2022-05-05 | Merck Sharp & Dohme Corp. | Macrocyclic urea orexin receptor agonists |
| EP4247801A4 (en) | 2020-11-23 | 2024-10-30 | Merck Sharp & Dohme LLC | 3-AMINO PYRROLIDINE AND MACROCYCLIC PIPERIDINE OREXIN RECEPTOR AGONISTS |
| US12552767B2 (en) | 2020-12-03 | 2026-02-17 | Merck Sharp & Dohme Llc | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| US12692262B2 (en) | 2020-12-16 | 2026-07-28 | Merck Sharp & Dohme Llc | Substituted ureas as orexin receptor agonists |
| US12006330B2 (en) * | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| JP7860139B2 (ja) | 2021-03-03 | 2026-05-15 | リサーチ トライアングル インスティテュート | オレキシン受容体アゴニストとしてのアリールスルホンアミド |
| WO2022207935A1 (en) | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
| MX2023012971A (es) | 2021-05-03 | 2024-01-16 | Jazz Pharmaceuticals Ireland Ltd | Agonistas del receptor de orexina y sus usos. |
| JPWO2022250108A1 (enExample) | 2021-05-26 | 2022-12-01 | ||
| EP4359387A1 (en) | 2021-06-25 | 2024-05-01 | Jazz Pharmaceuticals Ireland Limited | Sulfonamide orexin receptor agonists and uses thereof |
| WO2023017180A1 (en) | 2021-08-13 | 2023-02-16 | Orexia Therapeutics Limited | Peptide derivatives and related uses as orexin agonists |
-
2021
- 2021-12-20 US US17/556,250 patent/US12006330B2/en active Active
- 2021-12-21 EP EP21848371.7A patent/EP4263555A1/en active Pending
- 2021-12-21 JP JP2023536491A patent/JP2024501641A/ja active Pending
- 2021-12-21 CN CN202180080848.8A patent/CN116615427B/zh active Active
- 2021-12-21 WO PCT/US2021/064483 patent/WO2022140316A1/en not_active Ceased
- 2021-12-21 AU AU2021409403A patent/AU2021409403A1/en active Pending
- 2021-12-21 IL IL303848A patent/IL303848A/en unknown
- 2021-12-21 MX MX2023005338A patent/MX2023005338A/es unknown
- 2021-12-21 CA CA3172841A patent/CA3172841A1/en active Pending
- 2021-12-21 KR KR1020237024587A patent/KR20230127254A/ko active Pending
-
2024
- 2024-04-05 US US18/628,635 patent/US20240368182A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230127254A (ko) | 2023-08-31 |
| US20220194958A1 (en) | 2022-06-23 |
| AU2021409403A1 (en) | 2023-05-25 |
| CA3172841A1 (en) | 2022-06-30 |
| IL303848A (en) | 2023-08-01 |
| AU2021409403A9 (en) | 2025-03-20 |
| JP2024501641A (ja) | 2024-01-15 |
| CN116615427B (zh) | 2025-07-04 |
| CN116615427A (zh) | 2023-08-18 |
| US20240368182A1 (en) | 2024-11-07 |
| EP4263555A1 (en) | 2023-10-25 |
| WO2022140316A1 (en) | 2022-06-30 |
| US12006330B2 (en) | 2024-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202206482B (en) | Substituted macrocyclic compounds and related methods of treatment | |
| PH12021500030A1 (en) | Il-2 conjugates and methods of use thereof | |
| MX2021012638A (es) | Compuestos biciclicos. | |
| MX2023013173A (es) | Degradadores de cinasa 2 dependiente de ciclina (cdk2) y sus usos. | |
| MX2020011907A (es) | Inhibidores de kras g12c para el tratamiento de cancer. | |
| CY1125659T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| PH12023500015A1 (en) | Irak degraders and uses thereof | |
| PH12022551013A1 (en) | Pyridazinones as parp7 inhibitors | |
| MX2021012216A (es) | Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos. | |
| CR20240144A (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| PH12022551522A1 (en) | Smarca degraders and uses thereof | |
| WO2022251304A8 (en) | Substituted carbamate macrocyclic compounds and related methods of treatment | |
| CY1120373T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
| MX2020011344A (es) | Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios. | |
| MX2025008920A (es) | Inhibidores de parp1 triciclicos y usos de estos | |
| MX2023003973A (es) | Degradadores de transductores de señales y activadores de la transcripción (stat) y usos de los mismos. | |
| MX2026002406A (es) | Degradadores del transductor de señales y activador de la transcripción 6 (stat6) y usos de los mismos | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
| MX2022014007A (es) | Compuestos como inhibidores de bcl-2. | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| MX2025006853A (es) | Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos | |
| MX2022013954A (es) | Inhibidores de glucosilceramidasa no lisosomal y los usos de los mismos. | |
| WO2022221774A8 (en) | Aryl-ring-substituted 3-phenylazetidines and their use in methods for treating 5-ht2 responsive conditions | |
| MX2023007992A (es) | Compuestos cuadracíclicos fundidos, composiciones y usos de los mismos. |